05 April 2018 | News
Tecentriq has shown to extend survival and improve the quality of life in the approved indications.
Image credit- mayoclinic.org
Multinational healthcare company Roche has launched monoclonal antibody atezolizumab under the brand name Tecentriq in India for treatment of lung and bladder cancer.
According to Roche, Tecentriq has shown to extend survival and improve the quality of life in the approved indications. The product has been approved in India for two types of cancers- non-small cell lung cancer (NSCLC) and urothelial carcinoma, a type of bladder and urinary tract cancer.
The drug will now be available to patients in India on the prescription of oncologists. The company believes that Tecentriq will play an important role in the treatment of people with advanced bladder cancer and metastatic non-small cell lung cancer in India.